Foamix (FOMX) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. CDNS
5. ANT
6. SPY
7. META
8. HOOD
9. STX
10. INTC

Go back to Foamix (FOMX) Tops Q2 EPS by 10c

Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update

August 8, 2018 4:01 PM EDT

REHOVOT, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (Foamix or the Company), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today its financial results for the second quarter and six months ended June 30, 2018.

Clinical and Corporate Update:

The final patient was enrolled and dosed in the third Phase 3 study (FX2017-22) investigating FMX101, the Companys minocycline foam 4%, in patients with moderate-to-severe acne.- Top-line results are expected in... More